EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Pre-clinical pharmacology of beta-L-2,3-dideoxy-5-fluorocytidine and its prodrug bis- SATE-beta-L-2,3-dideoxy-5-fluorocytidine monophosphate



Pre-clinical pharmacology of beta-L-2,3-dideoxy-5-fluorocytidine and its prodrug bis- SATE-beta-L-2,3-dideoxy-5-fluorocytidine monophosphate



Antiviral Research 37(3): A64, March




(PDF emailed within 1 workday: $29.90)

Accession: 032898793

Download citation: RISBibTeXText



Related references

Studies of the pharmacokinetics and toxicology of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) in vivo; and synthesis and antiviral evaluations of 2',3'-dideoxy-beta-L-5-azacytidine. Nucleosides and Nucleotides 14(3-5): 619-625, 1995

Studies of the pharmacokinetics and toxicology of 2,3-dideoxy-beta-L-5-fluorocytidine and 2,3-dideoxy-beta-L-cytidine in vivo; and synthesis and antiviral evaluations of 2,3-dideoxy-beta-L-5-azacytidine. Nucleosides & Nucleotides 14(3-5): 619-625, 1995

Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochemical Pharmacology 47(2): 171-174, 1994

Immunomodulatory and antiviral activities of 2',3'-dideoxy-beta-L-cytidine and 2',3'-dideoxy-beta-L-5-fluorocytidine. Immunopharmacology and Immunotoxicology 17(1): 17-32, 1995

In vitro and in vivo metabolism and pharmacokinetics of bis -S-acyl-2-thioethyl-beta-2,3-dideoxy-5-fluorocytidine monophosphate. Nucleosides Nucleotides & Nucleic Acids 19(1-2): 481-499, 2000

Antiviral activity of 2,3-dideoxy-beta-L-5-fluorocytidine and 2,3-dideoxy-beta-L-cytidine against hepatitis B virus and human immunodeficiency virus type 1 in-vitro. Biochemical Pharmacology 47(2): 171-174, 1994

In vitro and in vivo metabolism and pharmacokinetics of bis ((T-butyl)-S-acyl-2-thioethyl)-beta-2',3'-dideoxy-5-fluorocytidine monophosphate. Nucleosides Nucleotides and Nucleic Acids 19(1-2): 481-499, 2000

In vitro and in vivo metabolism and pharmacokinetics of bis [(t-butyl)-S-acyl-2-thioethyl]-beta-L-2',3'-dideoxy-5-fluorocytidine monophosphate. Nucleosides, Nucleotides & Nucleic Acids 19(1-2): 481-499, 2000

Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys. Antimicrobial Agents and ChemoTherapy 49(7): 2589-2597, 2005

Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys. Antimicrobial Agents and ChemoTherapy 43(4): 920-924, 1999

Treatment of HIV by administration of beta-D-2, 3-didehydro-2,3-dideoxy-5-fluorocytidine. Official Gazette of the United States Patent & Trademark Office Patents 1246(3), May 15, 2001

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. Journal of Medicinal Chemistry 39(9): 1757-1759, 1996

Pharmacokinetics of beta-D-2,3-didehydro-2,3-dideoxy-5-fluorocytidine in rhesus monkeys. Antiviral Research 37(3): A47, March, 1998